This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Idiopathic Pulmonary Fibrosis Job Exposures Study (IPFJES)

This study is currently recruiting participants.
See Contacts and Locations
Verified July 2017 by Imperial College London
Sponsor:
Collaborator:
Wellcome Trust
Information provided by (Responsible Party):
Imperial College London
ClinicalTrials.gov Identifier:
NCT03211507
First received: May 2, 2017
Last updated: July 5, 2017
Last verified: July 2017
  Purpose
A case-control study to investigate whether job exposures are an under-recognized cause of idiopathic pulmonary fibrosis (IPF) using an interview to collect information about previous jobs and a blood test to investigate genetic susceptibility.

Condition Intervention
IPF Idiopathic Pulmonary Fibrosis Other: Computer-assisted telephone interview Genetic: Genetic analysis

Study Type: Observational
Study Design: Observational Model: Case-Control
Time Perspective: Prospective
Official Title: Idiopathic Pulmonary Fibrosis Job Exposures Study

Resource links provided by NLM:


Further study details as provided by Imperial College London:

Primary Outcome Measures:
  • Association between asbestos exposure and IPF [ Time Frame: 2 years ]
    estimated using logistic regression for any vs no asbestos exposure and adjusting for age and smoking status


Secondary Outcome Measures:
  • Dose-response relationship between asbestos exposure and IPF [ Time Frame: 2 years ]
    estimated using logistic regression for categories of cumulative exposure and adjusting for age and smoking status

  • Gene-environment interaction (for MUC5B rs35705950 and asbestos exposure) odds ratio. [ Time Frame: 2 years ]
    MUC5B rs35705950 and asbestos exposure odds ratio.


Biospecimen Retention:   Samples With DNA
blood

Estimated Enrollment: 920
Actual Study Start Date: May 1, 2017
Estimated Study Completion Date: October 5, 2020
Estimated Primary Completion Date: October 5, 2019 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Case
Males with an incident diagnosis of IPF
Other: Computer-assisted telephone interview
Occupational history
Genetic: Genetic analysis
To include analysis of known susceptibility markers
Controls
Males with an incident hospital outpatient attendance who do not have IPF
Other: Computer-assisted telephone interview
Occupational history
Genetic: Genetic analysis
To include analysis of known susceptibility markers

  Eligibility

Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Hospital based
Criteria

For cases

Inclusion Criteria:

  • New diagnosis of IPF between February 2017 and October 2019

Exclusion Criteria:

  • Unable to give informed consent
  • Ever worked outside of the UK

For controls

Inclusion Criteria:

  • New outpatient department attendee between February 2017 and October 2019

Exclusion Criteria:

  • Unable to give informed consent
  • Ever worked outside of the UK (does not include work outside the UK by members of the armed forces or merchant navy)
  • Diagnosis of IPF
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT03211507

Contacts
Contact: Carl Reynolds +44 (0)207 352 8121 ext 3364 carl.reynolds@imperial.ac.uk
Contact: Paul Cullinan p.cullinan@imperial.ac.uk

Locations
United Kingdom
Imperial Healthcare NHS Trust Recruiting
London, United Kingdom
Contact: Carl Reynolds, MBBS         
Sponsors and Collaborators
Imperial College London
Wellcome Trust
Investigators
Study Director: Carl Reynolds Imperial College London
  More Information

Additional Information:
Responsible Party: Imperial College London
ClinicalTrials.gov Identifier: NCT03211507     History of Changes
Other Study ID Numbers: 16SM3627
Study First Received: May 2, 2017
Last Updated: July 5, 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Fibrosis
Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis
Idiopathic Interstitial Pneumonias
Pathologic Processes
Lung Diseases
Respiratory Tract Diseases
Lung Diseases, Interstitial

ClinicalTrials.gov processed this record on August 18, 2017